Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study
Authors
Na Liu (ORCID: https://orcid.org/0000-0003-2276-3108)
Fangfang Wang (ORCID: https://orcid.org/0000-0002-5441-4490)
Haiyan Li (ORCID: https://orcid.org/0000-0003-4750-7477)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study
Na Liu, Fangfang Wang, Haiyan Li, Lisa Ying et al.
Journal
Frontiers in Pharmacology
Topics
Sphingolipid Metabolism and Signaling
article
Safety, tolerability, pharmacokinetics, and pharmacodynamics of etrasimod in healthy Chinese adults: a randomized, double-blind, placebo-controlled dose-escalation phase 1 study
Na Liu, Fangfang Wang, Haiyan Li, Lisa Ying, Zhiling Zhu, Yun Lin, Xiaoye Niu
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in PharmacologyVol. 16
Institutions
Peking University (CN), Peking University Third Hospital (CN), Zhejiang Medicine (China) (CN)